• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.10 -0.69 (-3.88%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,856,186
Open 17.82
Bid (Size) 16.65 (100)
Ask (Size) 17.12 (100)
Prev. Close 17.79
Today's Range 16.85 - 17.84
52wk Range 14.68 - 24.68
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
October 14, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
October 05, 2026
From Kahn Swick & Foti, LLC
Via Business Wire

Performance

52-Week Range 30.7% below 52-week high
17.10
14.6852W Low 24.6852W High
1 Week 5.7% below 1-week high
16.371W Low 18.141W High

Sarepta Therapeutics, Inc. - Common Stock (SRPT) traded between $14.68 and $24.68 over the past 52 weeks and last traded at $17.10, 30.7% below its 52-week high. Over the past week it ranged between $16.37 and $18.14.

Past 12 Months
-1.9%
-13.5%
-0.7%
-20.6%
-19.8%
-26.7%
1W -$0.34
1M -$2.66
3M -$0.12
6M -$4.45
YTD -$4.21
1Y -$6.24

SRPT was -26.7% over the past year, -20.6% over six months, -19.8% year to date, -1.9% in the last week.

12 Months vs Market
SRPT
-26.7%
DIA
+13.0%
SPY
+15.5%
QQQ
+18.3%
IWM
+10.4%

Over the past 12 months SRPT returned -26.7% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +10.4%.

Volume & Liquidity 3.16× 3-mo avg
Today 9,856,186 3-mo avg 3.1M
1W
4.7M
1M
3.2M
3M
3.1M
6M
3.2M
YTD
3.1M
1Y
3.4M

SRPT most recently traded 9,856,186 shares against a 3-month average daily volume of 3.1M.

More News

Read More
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics (NASDAQ:SRPT) Surges on Q2 Earnings Beat and Narrowed Outlook ↗
August 05, 2026
Via Chartmill
Topics Earnings
News headline image
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
September 30, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
September 25, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
September 24, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near ↗
September 15, 2026
Via MarketBeat
News headline image
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
September 08, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
August 31, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
August 24, 2026
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Sarepta (SRPT) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Sarepta Therapeutics Q2 Earnings Call Highlights ↗
August 06, 2026
Via MarketBeat
Topics Earnings
News headline image
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
August 05, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 29, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
July 27, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
July 22, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
2 Beaten-Down Stocks That Still Aren't Worth Buying ↗
July 11, 2026
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
June 30, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
June 03, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
June 01, 2026
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
From BioMedWire
Via GlobeNewswire
News headline image
My Top 3 Biotech Stocks for May 2026 ↗
May 20, 2026
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
The current price of Sarepta Therapeutics, Inc. - Common Stock is 17.10
When was Sarepta Therapeutics, Inc. - Common Stock last traded?
The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 1.59B
How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap